Maintenance Of Sinus Rhythm Research Articles

Plasma triglyceride is associated with the recurrence of atrial fibrillation after radiofrequency catheter ablation: A retrospective study.

The purpose of this study was to explore the association between triglycerides (TGs) and the risk of atrial fibrillation (AF) recurrence. Included were adult patients with AF who underwent radiofrequency catheter ablation in the Affiliated Changzhou Second People's Hospital of Nanjing Medical University. The enrolled patients were divided into theAF recurrence group and the sinus rhythm (SR) maintenance group. The univariate Cox regression analysis and Kaplan-Meier survival curve were performed estimate the association between TG and the risk of AF recurrence. Of the 402 patients, 79 (19.7%) experienced recurrence of AF after ablation. The TG level was significantly higher in the AF recurrence group than in the SR-maintaining group. Patients were grouped by quartile of TG levels, with Quartile 1 and Quartile 2 defined as the low concentration group, Quartile 3 as the moderate concentration group, and Quartile 4 as the high concentration group. Multivariate Cox regression analysis showed that the moderate concentration group (p = .02, hazard ratio [HR]: 2.331, 95% confidence interval [CI]: 1.141-4.762) and high concentration group (p = .007, HR: 2.873, 95% CI: 1.332-6.199) were associated with an increased risk of AF recurrence compared with the low concentration group. The median follow-up was 1.17 years, it is indicated that a higher risk of recurrent AF was observed in the moderate concentration and high concentration group (log-rank: χ2 = 7.540, p = .023). Our data suggest that an elevated TG level measured before catheter ablation is associated with an increased risk of AF recurrence.

Randomized Study Comparing Radiofrequency Ablation with the PVAC Gold System vs. Antiarrhythmic Drugs in Elderly Patients with Symptomatic Atrial Fibrillation.

There are no randomized studies comparing the maintenance of sinus rhythm after catheter ablation (CA) concerning treatment with antiarrhythmic drugs (AA) in elderly patients with paroxysmal atrial fibrillation (AF). To compare the clinical results of pulmonary vein (PV) isolation with the second-generation PVAC Gold catheter against AA treatment in elderly people with recurrent symptomatic paroxysmal AF, refractory to at least one AA, and without structural heart disease. Sixty patients with paroxysmal AF ≥ 65 years old were randomized to two forms of treatment: group 1: CA and group 2: AA drugs. The primary outcome was the AF recurrence-free rate after at least one year of follow-up. Secondary outcomes were: progression to persistent forms of AF, impact on quality of life (QOLF), and complications. The significance level adopted in the statistical analysis was 5% (p<0.05). The AF recurrence-free rate was 80% (10% with amiodarone) in the CA group, after 1.3 procedures per patient and 65% in the AA group (60% with amiodarone), (p = 0.119) in an average follow-up of 719 days (Q1: 566; Q3: 730). The persistent AF free rate was 83.4% in the AC group and 67.7% in the AA group (p = 0.073) Both strategies showed an improvement in the AFQoL score during follow-up (p < 0.001), with no difference between the groups. Although without clinical repercussions or impact on the intellectual assessment test, 25% of patients in the CA group showed signs of cerebral embolization on brain MRI. Both strategies for maintaining sinus rhythm promoted an improvement in the quality of life of elderly patients with symptomatic AF, with no statistical difference in the clinical outcomes. Additional studies using technologies with a better safety profile are needed to evaluate the benefits of CA in elderly patients with AF.

Clinical and instrumental factors associated with sinus rhythm maintenance following direct current cardioversion of late persistent non-valvular atrial fibrillation at 6-months follow-up

Abstract Purpose To study the clinical and instrumental factors, associated with sinus rhythm (SR) maintenance following direct current cardioversion (DCCV) in patients with late persistent non-valvular atrial fibrillation (AF) at 6-months follow-up. Methods The cohort single-center study analyzed clinical and instrumental data from 59 late persistent AF patients (with duration of its episode ≥90 days [up to 12 months]), who underwent an elective DCCV. At 6-months follow-up, 32 (54 %%) patients succeeded to maintain SR, in contrast to 27 (46 %) patients with a failure to its maintenance. Results The univariate logistic regression analysis revealed, that the absence of heart failure (HF) stage C (i.e., the presence of its stage B), the higher left ventricular ejection fraction (LVEF) (by transthoracic echocardiography [TTE]), left atrial appendage flow velocity (LAAFV) &amp;gt;40 cm/s and the freedom from left atrial spontaneous echo contrast (LASEC) (by transesophageal echocardiography), ‒ all were associated with the higher chance to maintain SR at 6-months follow-up (Figure). At the same time, the higher baseline left atrial dimension (LAD) and more advanced pulmonary hypertension (PH) (by TTE) were associated with the failure of its maintenance to be more probable (Figure). At multivariate analysis, the following predictors of SR maintenance after DCCV at 6-months follow-up were identified: higher LVEF (OR 1,07 (95 % CI 1,01-1,13); р=0,021); LAAFV &amp;gt;40 cm/s (OR 4,33 (95 % CI 1,06-17,78); р=0,042), and less advanced PH (OR 0,24 (95% CI 0,06-0,93); р=0,038). Conclusion Better LV systolic function, LAAFV &amp;gt;40 cm/s and less advanced PH were the predictors of SR maintenance following DCCV in patients with late persistent (with duration of its episode ≥90 days) non-valvular AF at 6-months follow-up.

Comparison of pulsed field ablation and thermal ablation for repeat procedures after failed prior thermal ablation for atrial fibrillation

Abstract Background Procedural efficiency and long-term clinical outcome after a first pulmonary vein isolation (PVI) for atrial fibrillation (AF) with pulsed-field ablation (PFA) has recently been reported to be non-inferior compared to radiofrequency ablation (RFA) and cryoballoon ablation (CBA). Studies comparing PFA and RFA for a first redo procedure in patients with failed prior thermal PVI are lacking. Purpose We sought to compare procedural efficiency and 1-year success rate (i.e maintenance of sinus rhythm) between PFA and RFA in patients undergoing a first redo procedure due to recurrence of atrial tachyarrhythmias after a prior thermal PVI. Methods Patients with recurrences after a 90-day blanking period following an index PVI with either RFA or CBA referred for a first redo ablation were enrolled. All redo procedures were done using a 3D electro-anatomical mapping to identify PV reconnections and guide repeat PVI by either PFA or RFA. In cases of incomplete or ostial isolation, the PFA group was treated using the standard 8-applications per vein while the CLOSE protocol was used for segmental PVI completion in the RFA group. Extra-PV lesion sets were added at the discretion of the treating physician. Patients were followed with 7d-Holter ECGs 3, 6, and 12 months after reablation. Recurring arrhythmias were categorized as persistent AF, paroxysmal AF, or atrial flutter. Secondary endpoints were periprocedural complications, total ablation time, radiation time and exposure. Results A total of 220 patients (median age 67 [IQR 58-74] years, 64% male, 64% persistent AF) were enrolled and equally treated with PFA or RFA (110 in both groups). There were no statistically significant differences in the clinical characteristics at baseline. Procedure time was shorter in the PFA group (95 vs. 122 minutes, p=0.001) whereas radiation time and dose were higher in the PFA group (17.0 vs. 6.4 minutes, p=&amp;lt;0.001 and 4.9 vs. 2.2 Gycm2, p=&amp;lt;0.001). Additional posterior wall ablation (PFA) or roof line (RFA) was performed predominantly in the PFA group (61 patients, 55.5 %) and in 5 patients (4.5 %) in the RFA group (p=0.001). Major complications occurred in 3 patients in the PFA group and in 1 patient in the RFA group (see Picture 2). Freedom from arrhythmia in Kaplan-Meier analysis 12 months after the reablation was 61% (CI 50-74%) in the PFA group and 59% (CI 49-71%; log-rank test p=0.81). No differences in outcomes were observed in the pooled group between paroxysmal AF (60%, CI: 50-72%) and persistent AF (61%, CI: 51-73%, p=0.64). Recurrence of organized atrial tachycardia was more common in the PFA group (p=0.018) Conclusion In patients undergoing a first redo procedure after a first round of thermal PVI and with recurrence of atrial tachyarrhythmia, PFA for reablation resulted in shorter procedure times compared to RFA despite more frequent posterior wall ablation. Long-term arrhythmia-free survival after the redo procedure was similar in both groups.Kaplan-Meier analysis of redo proceduresProcedure and outcome data

Sex-related differences in clinical outcomes of patients with atrial fibrillation and heart failure with preserved ejection fraction

Abstract Background Heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) are both highly prevalent diseases that commonly coexist, sharing clinical features and pathomechanisms. While prevalence of AF is higher in men compared to women with HFpEF, outcomes appear to be worse in women. However, there are no studies systematically examining gender-specific differences. Purpose Aiming for deeper insights into the effects of gender on clinical outcomes of patients with AF and HFpEF. Methods AF patients with HFpEF were included. HFpEF was diagnosed according to the current ESC guideline. Outcomes of men and women were compared. The primary endpoint was the time to heart failure hospitalization. Secondary endpoints were maintenance of sinus rhythm, as well as clinical and functional parameters. Factors related to a primary endpoint event were assessed. Results A total of 161 patients were included in our study (69 male patients, 92 female patients). Assessment of patient characteristics at baseline showed that male patients suffered more often from coronary artery disease (male: 45/69 patients (65%); female: 45/92 patients (49%); p=0.039), and OSAS (male: 14/69 patients (20%); female: 5/92 patients (5%); p=0.004). After a follow-up of 3 years, occurrence of the primary endpoint event was less frequent in women than in men (Hazard Ratio (HR): 0.61; 95% Confidence Interval (CI): 0.38-0.97; p=0.36; Figure A). By logistic regression analysis, we identified female sex (HR 0.48; 95%CI: 0.23-0.97; p=0.041), AF ablation (HR: 0.26; 0.13-0.53; p&amp;lt;0.001), and decrease in Left Ventricular Mass Index (LVMI) (HR:0.66; 95%CI: 0.44-0.98; p=0.041) as preventive factors with regard to heart failure hospitalization. Subgroup analysis for AF ablation versus medical therapy showed that patients who underwent ablation had lower hospitalization events (AF (HR: 0.49; 95% CI: 0.25-0.98; p=0.45). Additionally, left ventricular reverse remodeling, as assessed by the decrease of LVMI had a "dose-dependent" protective effect on heart failure hospitalizations (p=0.024, Figure B). Evaluation of functional HFpEF parameters revealed that only in women LVMI (baseline: 111 [99; 133] g/m2; follow-up: 105 [93; 127] g/m2; p=0.006), E/E’ ratio (baseline: 13.0 [10.2; 15.3]; follow-up: 11.5 [8.6; 14.7]; p=0.046), and NT-pro BNP serum levels (baseline: 1367 [352; 3605]; follow up: 987 [438; 2579]; p=0.039) improved. Discussion Our study suggests that women with AF and HFpEF have better outcomes as compared to men regarding heart failure hospitalization. LVMI and AF ablation are ssociated with fewer heart failure hospitalizations. Assessment of LVMI and further markers of HFpEF (E/E’ ratio and NT-pro BNP) only improved in women, suggesting that the gender-difference in heart failure hospitalization might be mediated by left ventricular induced remodeling following AF ablation. Further studies are necessary to verify this hypothesis generating results.Kaplan-Meier Analysis

The role of Ranolazine alone or in combination with a Class III anti-arrhythmic drug for DC cardioversion for persistent AF

Abstract Background Electrical cardioversion (DCCV) is commonly used for rhythm-control in patients with persistent AF. Use of anti-arrhythmic drugs (AADs) increases rates of acute conversion and longer-term maintenance of sinus rhythm (SR) following DCCV. Of these, Amiodarone is the most effective but has a high side-effect burden. Ranolazine, currently licensed for angina, has been shown to have AF-suppressive effects and works synergistically with Class III AADs. Purpose We aimed to assess outcomes following DCCV in patients treated with a Class III AAD, Ranolazine or in combination at a single UK tertiary Cardiology centre. Methods We retrospectively reviewed DCCV lists from June 2020-February 2022. Patients undergoing DCCV on a Class III AAD (Amiodarone/Dronedarone), Ranolazine or a combination of the two and with documented 1-year follow-up were included. Patients who underwent AF ablation during the follow-up period having remained in SR up to that point were excluded. Acute DCCV success and maintenance of SR at 1-year follow-up were recorded. Results A total of 350 patients underwent DCCV during the study period, of whom 102 (29.1%) were on an AAD. After exclusions, 78 patients were included, as follows: Amiodarone - n=30; Dronedarone - n=23; Ranolazine - n=11; combined Ranolazine + Class III AAD - n=14. Acute outcomes: The proportion of patients achieving SR acutely post-DCCV was as follows: Amiodarone: 27/30 (90.0%) Dronedarone: 21/23 (91.3%) Any Class III AAD: 48/53 (90.6%) Ranolazine: 10/11 (90.9 %) Combined Ranolazine + Class III AAD: 14/14 (100%). 1-year follow-up outcomes (Figure 1): The proportion of patients who had remained in SR at 1 year (mean follow-up 11±1.9 months – similar for all 4 groups) was as follows: Amiodarone: 12/30 (40.0%) Dronedarone: 4/23 (17.4%) Any Class III AAD: 16/53 (30.2%) Ranolazine: 3/11 (27.2%) Combined Ranolazine and Class III AAD: 8/14 (53.3%). Despite including 5 patients (35.3%) who had previously failed an AAD monotherapy, the group taking a combination of Ranolazine and a Class III AAD were numerically more likely to remain in SR at 1-year follow-up than those on Amiodarone or Ranolazine, though neither reached significance. However, combination therapy was significantly more effective than Dronedarone monotherapy (P=0.03) and there was a trend towards improved efficacy compared to any Class III AAD (53.3% vs. 30.2%, P=0.11). There were no significant differences between the 3 monotherapy treatments. Conclusion A combination of Ranolazine and Class III AAD may improve maintenance of SR 1 year post-DCCV compared to a Class III AAD alone. Ranolazine also shows comparable efficacy to traditional Class III agents and could therefore be considered as an alternative for patients in whom a Class III AAD is not desirable. Larger randomised multi-centre trials are warranted to evaluate the efficacy and safety of these treatment strategies.

Comparison of QT interval readings between smartwatch ECG combined with artificial intelligence and 12-lead ECG in subjects hospitalized for antiarrhythmic drug initiation and follow-up

Abstract Background/Introduction Class III antiarrhythmic drugs (AADs) are effective for the maintenance of sinus rhythm (SR) in subjects with atrial fibrillation (AF). However, several require initial hospitalization for QT interval monitoring using the 12-lead ECG. Purpose The purpose of this study was to evaluate the feasibility of using a smartwatch single lead ECG combined with a deep learning algorithm for routine QT interval determination in the context of AAD initiation. Methods A deep learning model was developed using smartwatch and Holter ECG recordings to estimate corrected QT intervals. To evaluate the performance of this model, we carried out a prospective study on subjects hospitalized for initiation of sotalol and/or dofetilide. Subjects recorded near simultaneous (maximal 2 minutes apart) smartwatch ECGs (Apple Watch Series 6) and 12-lead ECG (Mac 5500 HD ECG or GE Carescape B450) right before and 2-3 hours after drug administration twice a day for 2-3 days. Blinded double annotation followed by adjudication of disagreement provided a reference heart rhythm (NSR or AF) and QTc interval. The tangent method was used for QTc interval determination. Bland-Altman analysis was performed to assess the agreement between QTc measures. Results Fifty subjects (mean age 67.4±10.9 years, 64% male) were enrolled in the study from February 2022 to October 2022. Out of 386 monitoring visits, 321 near simultaneous pairs of ECGs were collected with a mean delay of +15.0±41.1s for the smartwatch ECG compared to the 12-lead ECG. Overall, a mean QTcF reference value of 419.9±34.0 ms was observed (435.2±38.4 ms for QTcB, r=0.83 between annotators[BL2] ). Among the 139 pairs with 12-lead ECG found in NSR, we observed a mean QTcF difference of +19.7 ms and limits of agreements equal to -21.5 ms and 60.8 ms, with AI-facilitated measurement. In comparison, a mean QTcF difference of +22.5 ms and limits of agreements equal to -23.8 ms and 68.8 ms were observed for manual readings of smartwatch ECGs instead. Conclusion(s): Our findings suggest that a smartwatch ECG deep learning approach can estimate the QT interval with a fair agreement compared to standard 12-lead monitoring during AAD initiation. This measurement method appears to be at least as accurate as manual measurements on smartwatch ECGs. With further validation, the smartwatch-based automatic detection of QT interval prolongation, could be used for a faster, safe, and extended outpatient QT interval monitoring.Bland-Altman plots

Atrial fibrillation after transcatheter tricuspid valve repair: rhythm control strategies and outcomes

Abstract Background Transcatheter tricuspid valve (TV) repair emerged as a viable treatment option in patients with severe tricuspid regurgitation and high operative risk. Although atrial fibrillation (AF) is common in these patients, the prognostic value of maintenance of sinus rhythm (SR) after transcatheter TV repair is unknown. Purpose We sought to assess the prevalence and efficacy of rhythm control strategies and impacts of maintenance of sinus rhythm on outcomes after transcatheter TV repair. Methods All patients undergoing transcatheter TV repair in our center between April 2017 and December 2022 were included in this single-center retrospective analysis. Patients who maintained SR throughout the follow-up (FU) were compared to patients who did not. The composite study endpoint included death from any cause, heart failure (HF) hospitalization and repeat TV repair. Furthermore, prevalence and efficacy of rhythm control strategies were evaluated. Results A total of 203 patients (mean age 78 ± 7 years, 145 (68 %) female) after transcatheter TV repair was analyzed. After a median follow-up of 12 months (IQR 4-20), 21 patients (10 %) did maintain SR. AF was present in 183 patients (90 %), of whom 134 had permanent AF. In the AF group, direct-current cardioversion (DCCV) was performed in 6 patients (3 %). Following DCCV, SR was restored in 4 patients (75 %), of whom 3 patients (75 %) presented in SR 30 days after DCCV. 2 patients (1 %) underwent AF ablation. After a case-control matching including 38 patients (SR vs. AF), during a median follow-up of 8 months (IQR 1-20) the study endpoint occurred in 7 of 19 patients (37 %) in the SR group and 12 of 19 patients (63 %) in the AF group (HR 0.70, p = 0.43). Conclusions The incidence of AF among patients undergoing transcatheter TV repair is high. In the present patient cohort, there was a trend towards a higher likelihood of death from any cause, HF hospitalization and repeat transcatheter TV repair in patients with AF. Further randomized studies are needed to evaluate the impact of rhythm control in patient undergoing TV repair.

The contribution of pulmonary veins to the mechanism of persistent AF is dependent on their extent of electrical connection

Abstract Introduction Success rate of pulmonary vein isolation (PVI) is lower in patients with persistent AF (peAF) compared to paroxysmal AF. The indiscriminate use of adjunctive catheter ablation (CA) strategies beyond PVI involve potential risks and new areas of iatrogenic arrhythmogenesis. Thus, distinguishing patients with peAF who may be cured with PVI-only from those who need CA beyond PVI would allow a more efficient patient-tailored CA strategy. Purpose We aimed to evaluate whether the circumferential extent of PV electrical connection assessed during pre-ablation mapping predicts the success rate of a PVI-only CA strategy. Methods Consecutive patients with peAF undergoing first CA consisting of a PVI-only CA were included. The extent of PV electrical connection was assessed using a circular mapping catheter placed within the PVs prior to ablation. Based on their follow-up (FU), patients were considered: a) PVI-responders, in the absence of AF or atrial flutter recurrence ≥ 12 months off-anti-arrhythmic drugs, b) PVI-non responders, in case of AF recurrence despite absence of any PV reconnection at reintervention, or despite one reintervention consisting of stand-alone residual PV connection ablation, c) PVI response was considered as indeterminate for all other instances (eg. Sinus rhythm maintenance on-AAD, shorter FU, etc). Results 148 patients were included (mean age 64 ± 9.7 years, mean peAF duration 7.3 ± 7 months). After a mean FU of 18 months after last PVI, we identified 60 PVI-responders and 25 PVI- non responders. In the remaining 63 patients, PVI response was indeterminate. In PVI-responders, the median percentage of the PV circumference displaying PVs potentials was significantly higher compared to PVI-non responders (68% vs. 60%, respectively; p=0.035). Conclusions The circumferential extent of PVs connection is correlated to the success rate of a stand-alone PVI CA strategy in patients with peAF. It may be a marker of the contribution of PVs to AF. Patients with poorly connected PVs during index CA ablation may warrant additional ablation strategies beyond PVI.

Atypical atrial flutter ablation: follow-up and predictors of arrhythmia recurrence

Background: Ablation techniques have evolved greatly with advances in high-density 3D mapping systems over the last few years. Some patients develop atypical atrial flutter (AAFL) after pulmonary vein isolation (PVI). The data regarding follow-up after AAFL ablation as well as predictors of arrhythmia recurrence are lacking. This analysis aims to report procedure success rates and establish predictors of long-term success. Methods and Results: This retrospective cohort study included 45 patients (median age: 69 years; 40% female) who qualified for their first AAFL after PVI. The procedures were performed with the use of conventional ablation-index-guided ThermoCool Smarttouch SF and QDOT MICRO catheters. Freedom from arrhythmia recurrence was used as a primary end point. After 52 weeks of follow-up, 60% of patients suffered from arrhythmia recurrence, but over 70% of the studied cohort reported symptom improvement. In multivariate analysis, class I antiarrhythmics prescription (HR = 0.24 [95% CI 0.06–0.94], p = 0.04) was associated with the lack of arrhythmia recurrence during the follow-up, while cardioversion during procedure was associated with increased risk of arrhythmia recurrence (HR = 7.05 [95% CI 2.09–23.72], p = 0.002). Conclusions: Long-term success of AAFL ablation procedures is not satisfactory despite improvement in symptoms. Class I antiarrhythmics prescription at the discharge contributes to higher chances of sinus rhythm maintenance, whereas cardioversion during the procedure is related to increased risk of arrhythmia recurrence.

ECG and Atrial Appendage Doppler Discordance Is Common in Patients Undergoing Cardiac Surgery: Prospective Study

BackgroundPatients with atrial fibrillation (AF) remain at increased risk of thromboembolism despite apparent maintenance of sinus rhythm with the cause often attributed to periods of asymptomatic AF. Atrial mechanical discordance, with the body of the left atrium (LA) in sinus rhythm and the left atrial appendage (LAA) in AF may also be a contributor. ObjectivesThe purpose of this study was to assess the frequency of electrocardiogram (ECG) rhythm and LAA and/right atrial appendage (RAA) Doppler ejection phenotype (transesophageal echocardiography [TEE]) discordance in patients undergoing cardiac surgery. MethodsA total of 124 patients undergoing coronary artery bypass graft (CABG), CABG and valve surgery, or isolated valve repair or replacement (valve ± CABG) were prospectively studied. Intraoperative surface ECG rhythm strip and TEE were performed before cardiopulmonary bypass. The ECG and TEE LAA/RAA Doppler spectrum were independently classified as sinus or AF. ResultsOf 107 patients (age 65 ± 12 years; 31% female; 65% CABG, 31% valve ± CABG) without a history of AF, 39 (36%) had ECG and LAA and/or RAA discordance (ECG/LAA Doppler discordance, n = 12 [11%]; ECG/RAA Doppler discordance, n = 35 [33%]). There was no significant difference between concordant and discordant groups with regard to age, gender, history of hypertension, diabetes, heart failure, or stroke (all P > 0.05). ConclusionsA large minority of patients without a history of AF undergoing cardiac surgery have ECG/atrial appendage Doppler discordance, a setting that may promote thromboembolism in non-anticoagulated patients. Clinical parameters do not identify patients at increased risk for discordance.

Comparison between catheter ablation versus permanent pacemaker implantation as an initial treatment for tachycardia–bradycardia syndrome patients: a prospective, randomized trial

BackgroundClinical outcomes after catheter ablation (CA) or pacemaker (PM) implantation for the tachycardia–bradycardia syndrome (TBS) has not been evaluated adequately. We tried to compare the efficacy and safety outcomes of CA and PM implantation as an initial treatment option for TBS in paroxysmal atrial fibrillation (AF) patients.MethodsSixty-eight patients with paroxysmal AF and TBS (mean 63.7 years, 63.2% male) were randomized, and received CA (n = 35) or PM (n = 33) as initial treatments. The primary outcomes were unexpected emergency room visits or hospitalizations attributed to cardiovascular causes.ResultsIn the intention-to-treatment analysis, the rates of primary outcomes were not significantly different between the two groups at the 2-year follow-up (19.8% vs. 25.9%; hazard ratio (HR) 0.73, 95% confidence interval (CI) 0.25–2.20, P = 0.584), irrespective of whether the results were adjusted for age (HR 1.12, 95% CI 0.34–3.64, P = 0.852). The 2-year rate of recurrent AF was significantly lower in the CA group compared to the PM group (33.9% vs. 56.8%, P = 0.038). Four patients (11.4%) in the CA group finally received PMs after CA owing to recurrent syncope episodes. The rate of major or minor procedure related complications was not significantly different between the two groups.ConclusionCA had a similar efficacy and safety profile with that of PM and a higher sinus rhythm maintenance rate. CA could be considered as a preferable initial treatment option over PM implantation in patients with paroxysmal AF and TBS.Trial registrationKCT0000155.

Efficacy of Shensong Yangxin capsule combined with dronedarone in paroxysmal atrial fibrillation after ablation.

To investigate whether postoperative administration of Shensong Yangxin capsules (SSYX) and dronedarone for atrial fibrillation (AF) can reduce the recurrence of paroxysmal AF after radiofrequency ablation, thus providing a more optimal choice of antiarrhythmic medication during the blank period. We included 120 patients with paroxysmal AF who underwent radiofrequency ablation at our hospital between July 2020 and July 2022. They underwent routine circumferential pulmonary vein ablation and, subsequently, left and right atrial pressure monitoring to assess sinoatrial node recovery time under burst 400/300 ms stimulation. Postoperatively, the patients were randomly divided into 2 groups (60 patients each). The control group was administered dronedarone orally for 3 months and the study group was treated with SSYX combined with dronedarone. This study aimed to compare differences in clinical efficacy of the treatment between the 2 groups. The left and right atrial pressures in both groups were higher than those in the preoperative period (P < .05), with no statistically significant differences between the 2 groups (P > .05). Sinoatrial node recovery time under burst 400/300 ms stimulation showed no statistical difference between the 2 groups (P > .05). At 3 months and 1 year postoperatively, the AFEQT scale scores for both groups were lower than those before treatment (P < .05), with the study group scoring lower than the control group at 3 months (P < .05). However, no statistically significant difference was observed between the 2 groups at 1 year postoperatively (P > .05). At 3 months postoperatively, the sinus rhythm maintenance rate and heart rate were higher in the intervention group than in the control group (P < .05); however, these differences between the 2 groups were not statistically significant at 1 year postoperatively (P > .05). The combination of SSYX and dronedarone could effectively reduce the early recurrence of paroxysmal AF after radiofrequency ablation, increase heart rate, and improve the quality of life.

Efficacy of catheter ablation for atrial fibrillation in heart failure: a meta-analysis of randomized controlled trials.

The study aims to evaluate whether rhythm control by catheter ablation is superior to medical therapy for the patients with atrial fibrillation (AF) and heart failure (HF). The literatures were searched by using PubMed, Cochrane Library, Embase, and Web of Science databases up to 12 October 2023. The randomized controlled trials (RCTs) comparing rhythm control using catheter ablation vs. medical therapy in AF patients with HF were pooled. The primary outcomes included all-cause mortality, HF re-hospitalization, and stroke, and the secondary outcomes included left ventricular ejection fraction (LVEF), atrial tachyarrythmia recurrence, quality of life (Minnesota Living with Heart Failure Questionnaire score, MLHFQ score), 6min walking distance (6MWD), the level of N-terminal B-type natriuretic peptide precursor (NT-proBNP), and adverse events. Nine RCTs involving in 2293 patients met the inclusion criteria. Compared with medical therapy, catheter ablation reduced all-cause mortality [10.07% (121/1201) vs. 15.26% (175/1147), risk ratio (RR):0.60, 95% confidence interval (CI): 0.48-0.74, P<0.00001, I2=0%] and the rate of HF re-hospitalization (RR: 0.65, P=0.02, 95% CI: 0.45 to 0.94, I2=74%), but had no obvious difference in incidence of stroke (RR: 0.67, P=0.27, 95% CI: 0.32 to 1.38, I2=0%). Catheter ablation enhanced LVEF [mean difference (MD), 6.26%, P<0.00001, I2=89%], reduced AT recurrence (RR: 0.37, P<0.00001, 95% CI: 0.26 to 0.52, I2=89%), improved the quality of life (MLHFQ score) (MD: -6.83, P=0.003, I2=67%), elevated 6MWD (MD: 15.92, P=0.006, I2=76%), and diminished the level NT-proBNP (MD: -44.19, P<0.00001, I2=75%), but had no significant difference in adverse events [25.81% (310/1201) vs. 30.25% (347/1147), RR: 0.81, 95% CI: 0.65-1.01, P=0.06, I2=55%]. Catheter ablation as rhythm control strategy substantially enhances the survival rate, reduces HF re-hospitalization, increases the rate of sinus rhythm maintenance, improves the left ventricular function and the quality of life for AF patients with HF, and has similar safety, compared with medical therapy. The rhythm control by catheter ablation may be a better strategy for the AF patients with HF.

Comparison of short-term efficacy of two bipolar radiofrequency ablation forceps for rheumatic heart disease concomitant with atrial fibrillation.

Currently, the bipolar radiofrequency ablation forceps manufactured by AtriCure are the main instrument for surgical ablation in patients with rheumatic heart disease (RHD) concomitant with atrial fibrillation (AF). The bipolar radiofrequency ablation forceps by Med-Zenith has a greater advantage in price compared with AtriCure. However, few studies have been reported on the comparison of their clinical efficacy. The aim of this study is to compare the short-term clinical efficacy of the two ablation forceps for RHD concomitant with AF. Clinical data of 167 patients with RHD concomitant with AF admitted to the Department of Cardiac Major Vascular Surgery, Affiliated Hospital of North Sichuan Medical College, were retrospectively analyzed, and the restoration efficacy of sinus rhythm (SR) and cardiac function after surgery were compared with two ablation forceps. The end-systolic diameter of the right atrium and the end-systolic diameter of the left atrium in the patients of both groups at each postoperative time point decreased compared with that of the preoperative period (P < 0.05), and the left ventricular ejection fraction started to improve significantly at 6 months after surgery compared with that of the preoperative period (P < 0.05). There was no difference between the two groups of patients in the comparison of the aforementioned indicators at different points in time (P > 0.05). At 12 months postoperatively, the SR maintenance rate in using the ablation forceps by Med-Zenith (73.3%) was lower than that for AtriCure (86.4%) and the cumulative recurrence rate of AF in using the Med-Zenith ablation forceps was greater than that for AtriCure. The two bipolar radiofrequency ablation forceps compared in the study are safe and effective in treating patients of RHD concomitant with AF, and the ablation forceps by AtriCure may be more effective in restoring SR in the short term.

Atrial fibrillation: real-life experience of a rhythm control with electrical cardioversion in a community hospital

BackgroundAtrial fibrillation is the most prevalent sustained cardiac arrhythmia. Electrical cardioversion, a well-established part of the rhythm control strategy, is probably underused in community settings. Here, we describe its use, safety, and effectiveness in a cohort of patients with atrial fibrillation treated in rural settings.MethodsIt is a retrospective cohort study. Data on all procedures from January 1, 2016, till December 1, 2022, in Tarusa Hospital, serving mostly a rural population of 15,000 people, were extracted from electronic health records. Data on the procedure’s success, age, gender, body mass index, comorbidities, previous procedures, echocardiographic parameters, type and duration of arrhythmia, anticoagulation, antiarrhythmic drugs, transesophageal echocardiography, and settings were available.ResultsAltogether, 1,272 procedures in 435 patients were performed during the study period. The overall effectiveness of the procedure was 92%. Effectiveness was similar across all prespecified subgroups. Electrical cardioversion was less effective in patients undergoing the procedure for the first time (86%, 95% CI: 82-90) compared to repeated procedures (95%, 95% CI: 93-96), OR 0.39 (95% CI: 0.26-0.59). Complications were encountered in 13 (1.02%) procedures but were not serious.ConclusionsElectrical cardioversion is an immediately effective procedure that can be safely performed in community hospitals, both in inpatient and outpatient settings. Further studies with longer follow-up are needed to investigate the rate of sinus rhythm maintenance in these patients.

MicroRNAs in Atrial Fibrillation: Mechanisms, Vascular Implications, and Therapeutic Potential.

Atrial fibrillation (AFib), the most prevalent arrhythmia in clinical practice, presents a growing global health concern, particularly with the aging population, as it is associated with devastating complications and an impaired quality of life. Its pathophysiology is multifactorial, including the pathways of fibrosis, inflammation, and oxidative stress. MicroRNAs (miRNAs), small non-coding RNA molecules, have emerged as substantial contributors in AFib pathophysiology, by affecting those pathways. In this review, we explore the intricate relationship between miRNAs and the aforementioned aspects of AFib, shedding light on the molecular pathways as well as the potential diagnostic applications. Recent evidence also suggests a possible role of miRNA therapeutics in maintenance of sinus rhythm via the antagonism of miR-1 and miR-328, or the pharmacological upregulation of miR-27b and miR-223-3p. Unraveling the crosstalk between specific miRNA profiles and genetic predispositions may pave the way for personalized therapeutic approaches, setting the tone for precision medicine in atrial fibrillation.

Catheter ablation of atrial arrhythmias in cardiac amyloidosis: Impact on heart failure and mortality.

Atrial arrhythmias (AA) commonly affect patients with cardiac amyloidosis (CA) and are a contributing risk factor for the development of heart failure (HF). This study sought to investigate the long-term efficacy and impact of catheter ablation on HF progression in patients with CA and AA. Thirty-one patients with CA and AA undergoing catheter ablation were retrospectively included (transthyretin-ATTR CA 61% and light chain-AL CA 39%). AA subtypes included atrial fibrillation (AFib) in 22 (paroxysmal in 10 and persistent in 12), atrial flutter (AFl) in 17 and atrial tachycardia (AT) in 11 patients. Long-term AA recurrence rates were evaluated along with the impact of sinus rhythm (SR) maintenance on HF and mortality. AA recurrence was observed in 14 patients (45%) at a median of 3.5 months (AFib n = 8, AT n = 6, AFl = 0). Post-cardioversion, medical therapy or catheter ablation, 10 patients (32%) remained in permanent AA. Over a median follow-up of 19 months, all-cause mortality was 39% (n = 12): 3 with end-stage HF, 5 due to late complications of CA, 1 sudden cardiac death, 1 stroke, 1 COVID 19 (and one unknown). With maintenance of SR following catheter ablation, significant reductions in serum creatinine and natriuretic peptide levels were observed with improvements in NYHA class. Two patients required hospitalization for HF in the SR maintenance cohort compared to 5 patients in the AA recurrence cohort (p = 0.1). All 3 patients with deaths secondary to HF had AA recurrence compared to 11 out of the 28 patients whom were long-term survivors or deaths not related to HF (p = 0.04). All-cause mortality was not associated with AA recurrence. This study demonstrates moderate long-term efficacy of SR maintenance with catheter ablation for AA in patients with CA. Improvements in clinical and biological status with positive trends in HF mortality are observed if SR can be maintained.

Comorbid Patients with Abdominal Obesity and High Risk of Atrial Fibrillation: Correction of Modifiable Risk Factors as a Strategy of Primary Prevention (Prospective Study)

Aim. To assess whether correction of modifiable risk factors is efficient to prevent atrial fibrillation (AF) in comorbid patients with abdominal obesity and premature atrial contractions.Materials and Methods. We enrolled 889 comorbid patients with abdominal obesity and premature atrial contractions, aged from 58 to 72 years (average age 66.4 ± 0.7 years). The duration of follow-up was 3 years. All patients underwent correction of potentially modifiable risk factors of AF (normalisation of body weight, blood pressure, blood glucose and lipid levels, cessation of smoking, elimination of physical inactivity) until their target values were achieved. Endpoints included maintenance of sinus rhythm or registration of AF. After the follow-up, all patients could be divided into two groups: 578 (65.02%) patients with incomplete correction of risk factors, 95 (10.69%) patients who achieved target values, and 216 (24.29%) without risk factor correction.Results. Within the first two years of follow-up, the frequency of AF did not differ significantly and was 85.29%, 94.32%, and 93.47% respectively. In patients who achieved target values of potentially modifiable risk factors for &gt; 1 year, the ratio of actual to predicted development of AF during the 2nd and 3rd year of follow-up was 57.58% and 14.29%, respectively.Conclusion. In comorbid patients with abdominal obesity and premature atrial contractions, reduction of AF was observed exclusively in patients with successful correction of all potentially modifiable risk factors for ≥ 2 years.

Arrhythmias in Patients with Pulmonary Hypertension and Right Ventricular Failure: Importance of Rhythm Control Strategies.

Arrhythmias frequently complicate the course of advanced pulmonary hypertension, often leading to hemodynamic compromise, functional impairment, and mortality. Given the importance of right atrial function in this physiology, the restoration and maintenance of sinus rhythm are of critical importance. In this review, we outline the pathophysiology of arrhythmias and their impact on right heart performance; describe considerations for antiarrhythmic drug selection, anesthetic and periprocedural management; and discuss the results of catheter ablation techniques in this complex and challenging patient population.